Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Patil, R. Figlin, Thomas Hutson, D. Michaelson, S. Négrier, S. Kim, Xin Huang, R. Motzer (2010)
TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α).Journal of Clinical Oncology, 28
H. Mouridsen (2007)
Letrozole in advanced breast cancer: the PO25 trialBreast Cancer Research and Treatment, 105
J. Robertson, A. Llombart-Cussac, J. Rolski, D. Feltl, J. Dewar, E. Macpherson, J. Lindemann, M. Ellis (2009)
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
M. Dowsett, T. Nielsen, R. A’Hern, J. Bartlett, R. Coombes, J. Cuzick, M. Ellis, N. Henry, J. Hugh, T. Lively, L. McShane, S. Paik, F. Penault-Llorca, Ljudmila Prudkin, M. Regan, J. Salter, C. Sotiriou, I. Smith, G. Viale, J. Zujewski, D. Hayes (2011)
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.Journal of the National Cancer Institute, 103 22
J. Woodcock, R. Behrman, A. Lindsay, R. Choudhury, R. Wetsel (2011)
Mechanisms of endocrine resistance in breast cancer.Annual review of medicine, 62
G. Clark, C. Osborne, W. McGuire (1984)
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2 10
S. Stockwell (1983)
Classics in oncology: George thomas beatson m.d.(1848‐1933)CA: A Cancer Journal for Clinicians, 33
J. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, M. Voneuler (2000)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 22
K. Hur, F. Balaguer, Masanobu Takahashi, T. Nagasaka, J. Koike, H. Hemmi, M. Koi, C. Boland, A. Goel (2011)
Abstract 95: Increased hypomethylation of LINE-1 and Alu in human colorectal cancer metastasisCancer Research, 71
T. Bachelot, C. Bourgier, C. Cropet, J. Guastalla, J. Ferrero, C. Léger-Falandry, P. Soulié, J. Eymard, M. Debled, D. Spaeth, E. Legouffe, T. Delozier, C. Kouri, J. Chidiac (2010)
Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).Cancer Research, 70
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, Fred Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 16
K. Voduc, Maggie Cheang, S. Tyldesley, K. Gelmon, Torsten Nielsen, H. Kennecke (2010)
Breast cancer subtypes and the risk of local and regional relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
E. Levin, R. Pietras (2008)
Estrogen receptors outside the nucleus in breast cancerBreast Cancer Research and Treatment, 108
A. Milla-Santos, L. Millá, J. Portella, L. Rallo, M. Pons, E. Rodes, J. Casanovas, Margarita Puig-Gali (2003)
Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer: A Prospective, Randomized, Phase III StudyAmerican Journal of Clinical Oncology, 26
H. Mehta, Q. Gao, C. Galet, Vladislava Paharkova, J. Wan, J. Said, Joanne Sohn, G. Lawson, P. Cohen, L. Cobb, Kuk-Wha Lee (2011)
IGFBP-3 is a metastasis suppression gene in prostate cancer.Cancer research, 71 15
I. Smith, G. Walsh, A. Skene, A. Llombart, J. Mayordomo, S. Detre, J. Salter, E. Clark, P. Magill, M. Dowsett (2007)
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 25
T. Traina, H. Rugo, J. Caravelli, S. Patil, B. Yeh, M. Melisko, John Park, S. Geneus, Matthew Paulson, J. Grothusen, A. Seidman, M. Fornier, D. Lake, C. Dang, M. Robson, M. Theodoulou, C. Flombaum, L. Norton, C. Hudis, M. Dickler (2010)
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
R. Paridaens, L. Dirix, L. Beex, M. Nooij, D. Cameron, T. Čufer, M. Piccart, J. Bogaerts, P. Therasse (2008)
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30
R. Schiff, S. Massarweh, J. Shou, L. Bharwani, S. Mohsin, C. Osborne (2004)
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine ResistanceClinical Cancer Research, 10
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
M. Goetz, S. Knox, V. Suman, J. Rae, Stephanie Safgren, M. Ames, D. Visscher, C. Reynolds, F. Couch, W. Lingle, R. Weinshilboum, E. Fritcher, Andrea Nibbe, Z. Desta, A. Nguyen, D. Flockhart, E. Perez, J. Ingle (2006)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenBreast Cancer Research and Treatment, 101
A. Howell, J. Robertson, P. Abram, M. Lichinitser, R. Elledge, E. Bajetta, Toru Watanabe, C. Morris, A. Webster, I. Dimery, C. Osborne (2004)
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
H. Mouridsen, Yan Sun, M. Gershanovich, R. Pérez-Carrión, D. Becquart, H. Chaudri-Ross, R. Lang (2004)
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.The oncologist, 9 5
J. Baselga, V. Semiglazov, P. Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H. Lane, J. Dixon, W. Jonat, H. Rugo (2009)
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 16
A. Howell, J. Pippen, R. Elledge, L. Mauriac, I. Vergote, Stephen Jones, S. Come, C. Osborne, J. Robertson (2005)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinomaCancer, 104
E. Jensen, E. Desombre (1972)
Mechanism of action of the female sex hormones.Annual review of biochemistry, 41
J. Bonneterre, B. Thürlimann, J. Robertson, M. Krzakowski, L. Mauriac, P. Koralewski, I. Vergote, A. Webster, M. Steinberg, M. Euler (2000)
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 22
S. Chia, W. Gradishar, L. Mauriac, J. Bines, F. Amant, M. Federico, L. Fein, G. Romieu, A. Buzdar, J. Robertson, A. Brufsky, K. Possinger, P. Rennie, F. Sapunar, E. Lowe, M. Piccart (2008)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
S. Johnston, J. Pippen, X. Pivot, M. Lichinitser, S. Sadeghi, V. Diéras, H. Gómez, G. Romieu, A. Manikhas, M. Kennedy, M. Press, J. Maltzman, A. Florance, L. O’Rourke, C. Oliva, S. Stein, M. Pegram (2009)
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
C. Osborne, J. Pippen, S. Jones, Leroy Parker, M. Ellis, S. Come, Stan Gertler, J. May, Gary Burton, I. Dimery, A. Webster, C. Morris, R. Elledge, Aman Buzdar (2002)
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
R. Santen, P. Fan, Zhenguo Zhang, Y. Bao, R. Song, W. Yue (2009)
Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cellsSteroids, 74
C. Osborne, P. Neven, L. Dirix, J. Mackey, J. Robert, C. Underhill, R. Schiff, C. Gutierrez, I. Migliaccio, V. Anagnostou, D. Rimm, P. Magill, M. Sellers (2011)
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II StudyClinical Cancer Research, 17
M. Cristofanilli, V. Valero, A. Mangalik, M. Royce, I. Rabinowitz, F. Arena, J. Kroener, E. Curcio, C. Watkins, S. Bacus, E. Cora, Elizabeth Anderson, P. Magill (2010)
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast CancerClinical Cancer Research, 16
J. Robertson, W. Odling‐Smee, C. Holcombe, S. Kohlhardt, M. Harrison (2003)
Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer.Clinical therapeutics, 25 5
M. Gutiérrez, S. Detre, S. Johnston, S. Mohsin, J. Shou, D. Allred, R. Schiff, C. Osborne, M. Dowsett (2005)
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
V. Dezentjé, N. Blijderveen, H. Gelderblom, H. Putter, M. Herk-Sukel, M. Casparie, A. Egberts, J. Nortier, H. Guchelaar (2010)
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 14
Anthony Howell, J. Robertson, J. Albano, A. Aschermannová, L. Mauriac, U. Kleeberg, I. Vergote, B. Erikstein, A. Webster, Charles Morris (2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
J. Klijn, L. Beex, L. Mauriac, Jacobus Zijl, C. Veyret, J. Wildiers, J. Jassem, M. Piccart, J. Burghouts, D. Becquart, Carolien Seynaeve, F. Mignolet, L. Duchateau (2000)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.Journal of the National Cancer Institute, 92 11
A. Leo, G. Jerusalem, L. Petruželka, R. Torres, I. Bondarenko, R. Khasanov, D. Verhoeven, J. Pedrini, I. Smirnova, M. Lichinitser, K. Pendergrass, Sally Garnett, J. Lindemann, F. Sapunar, Miguel Martín (2010)
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 30
V. Devita, S. Hellman, S. Rosenberg (1982)
Cancer : Principles and Practice of Oncology
B. Thürlimann, J. Robertson, J. Nabholtz, Aman Buzdar, J. Bonneterre (2003)
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.European journal of cancer, 39 16
R. Mehta, W. Barlow, K. Albain, T. Vandenberg, S. Dakhil, Nagendra Tirumali, D. Lew, D. Hayes, J. Gralow, R. Livingston, G. Hortobagyi (2011)
S1-1: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226.Cancer Research, 71
M. Ellis, F. Gao, F. Dehdashti, D. Jeffe, P. Marcom, L. Carey, M. Dickler, P. Silverman, G. Fleming, A. Kommareddy, S. Jamalabadi-Majidi, R. Crowder, B. Siegel (2009)
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.JAMA, 302 7
J. Baselqa, M. Campone, T. Sahmoud, M. Piccart, H. Burris, H. Rugo, S. Noguchi, M. Gnant, P. Mukhopadhyay, G. Hortobagyi (2011)
Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III TrialEuropean Journal of Cancer, 47
J. Bergh, P. Jönsson, E. Lidbrink, M. Trudeau, W. Eiermann, D. Brattstrom, J. Lindemann, F. Wiklund, R. Henriksson (2009)
First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast CancerCancer Research, 69
J. Robertson, J. Lindemann, A. Llombart-Cussac, J. Rolski, D. Feltl, J. Dewar, L. Emerson, A. Dean, M. Ellis (2010)
Abstract S1-3: A Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the ‘FIRST’ StudyCancer Research, 70
B. Kaufman, J. Mackey, M. Clemens, P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, C. Révil, A. Jones (2009)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
D. Mauri, N. Pavlidis, N. Polyzos, J. Ioannidis (2006)
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.Journal of the National Cancer Institute, 98 18
D. Jelovac, L. Macedo, O. Goloubeva, Venkatesh Handratta, A. Brodie (2005)
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.Cancer research, 65 12
L. Martin, I. Farmer, S. Johnston, Simak Ali, C. Marshall, M. Dowsett (2003)
Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation*Journal of Biological Chemistry, 278
L. Macedo, G. Sabnis, O. Goloubeva, A. Brodie (2008)
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.Cancer research, 68 9
C. Liedtke, C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S. Kau, W. Symmans, C. Albarracin, F. Meric-Bernstam, W. Woodward, R. Theriault, L. Kiesel, G. Hortobagyi, L. Pusztai, A. González-Angulo (2009)
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 12
Anthony Howell, J. Robertson, I. Vergote (2003)
A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral MetastasesBreast Cancer Research and Treatment, 82
P. Lønning, P. Taylor, G. Anker, J. Iddon, Liv Wie, Linn-Marie Jørgensen, O. Mella, A. Howell (2001)
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapyBreast Cancer Research and Treatment, 67
H. Mouridsen, M. Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, A. Monnier, J. Apffelstaedt, Robert Smith, H. Sleeboom, F. Jaenicke, A. Płużańska, M. Dank, D. Becquart, P. Bapsy, E. Salminen, R. Snyder, H. Chaudri-Ross, R. Lang, P. Wyld, A. Bhatnagar (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 11
P. Goss, J. Ingle, S. Martino, N. Robert, H. Muss, M. Piccart, M. Castiglione, D. Tu, L. Shepherd, K. Pritchard, R. Livingston, N. Davidson, L. Norton, E. Perez, J. Abrams, D. Cameron, M. Palmer, J. Pater (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.Journal of the National Cancer Institute, 97 17
M. Lupien, Clifford Meyer, S. Bailey, J. Eeckhoute, J. Cook, T. Westerling, Xiaoyang Zhang, J. Carroll, D. Rhodes, X. Liu, Myles Brown (2010)
Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.Genes & development, 24 19
A. Jemal, R. Siegel, Jiaquan Xu, Elizabeth Ward (2010)
Cancer Statistics, 2010CA: A Cancer Journal for Clinicians, 60
P. Morrow, Ruben Serna, K. Broglio, L. Pusztai, D. Nikoloff, G. Hillman, M. Fontecha, Rui Li, L. Michaud, G. Hortobagyi, A. González-Angulo (2012)
Effect of CYP2D6 polymorphisms on breast cancer recurrenceCancer, 118
L. Macedo, G. Sabnis, A. Brodie (2008)
Preclinical modeling of endocrine response and resistanceCancer, 112
J. Ingle, V. Suman, K. Rowland, D. Mirchandani, A. Bernath, J. Camoriano, P. Fishkin, D. Nikcevich, E. Perez (2006)
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 7
R. Dickson, G. Stancel (2000)
Estrogen receptor-mediated processes in normal and cancer cells.Journal of the National Cancer Institute. Monographs, 27
R. Song, G. Mor, F. Naftolin, R. McPherson, Joon Song, Zhenguo Zhang, W. Yue, Ji-ping Wang, R. Santen (2001)
Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17β-EstradiolJournal of the National Cancer Institute, 93
New therapies and advances in molecular biology provide opportunities for progress in the management of patients with advanced estrogen receptor-positive breast cancer. The near universal exposure of patients with early stage disease to endocrine therapy poses challenges of resistance when disease recurs. Analysis of tumor tissue at the time of recurrence, and after subsequent endocrine therapy where possible, is critical to understanding the most productive strategies for development and ultimately for individual patients.
Current Breast Cancer Reports – Springer Journals
Published: Jan 7, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.